TT treatment increased the expression levels of fatty acid oxidation genes, including PPARα, and the mRNA levels of CPT1a and decreased the expression of lipogenic FAS and PPARγ and hepatic mRNA levels of SREBP1c, aP2, and GPAT, with the net effect of lowering blood triglycerides, hepatic steatosis, and total cholesterol levels. The gene discussed is FABP4; the disease is fatty liver disease.